Organic Active Ingredients TRIZ Cases

Nitrogen-substituted pyrimidine compounds inhibit mutant epidermal growth factor receptors to reduce dose-limiting toxicity from wild-type inhibition.

Measuring microRNA-150 expression levels identifies taxane-resistant ovarian cancer cells to guide targeted treatment strategies.

Segmented peptide amphiphiles boost retroviral transduction while ensuring rapid cellular degradation to prevent cytotoxicity.

Pseudozyma microorganisms produce mannosylerythritol lipid with specific fatty acid chains for industrial applications.

Optimized polysaccharides maintain viscosity under acidic conditions, creating a stable protective layer that extends symptom relief duration.

Enriching tetra, penta, and trimeric galacto-oligosaccharides while removing monosaccharides eliminates competing substrates to enhance bacterial colonization.

S-enantiomerically enriched oxprenolol compositions treat acute muscle weakness by isolating the active therapeutic enantiomer from racemic mixtures.

Oral 5-hydroxy-1-methylhydantoin prevents cancer recurrence by blocking carcinogenesis without the side effects of conventional therapies.

Amorphous propranolol ionic liquids reduce skin irritation by replacing crystalline free base formulations while maintaining transdermal flux.

A 2-methylene-19,21-dinorvitamin D3 analog binds vitamin D receptors to transport intestinal calcium.

Stable fumagillol carbamate polymorphs resolve self-condensation and hydrolysis issues during polymer conjugation.

Purified crocetinic acid targets pancreatic cancer stem cells by inhibiting the sonic hedgehog signaling pathway.

A nutraceutical composition combining Curcuma genus extract, alpha lipoic acid, and coenzyme Q10 to enhance sperm parameters.

Andrographolide reduces muscle-associated fibrosis by inhibiting CTGF, addressing severe side effects of glucocorticoid therapies.

TLR7/8 inhibitors block osteoclast differentiation, reducing bone resorption and physical impairment in chronic joint diseases.

A methylphenidate chewable tablet uses a barrier coated ion exchange resin complex to maintain extended release properties.

Combining NAMPT inhibitors with NAD precursors targets cancer cells while sparing normal tissue.

Hydration softens the polymer matrix, resolving rigidity gaps and improving comfort during wear.

High HLB emulsifiers create a self-emulsifying omega-3 system that ensures reliable absorption under fasting conditions.

Daurichromenic acid treats beta coronaviruses while avoiding central nervous system penetration.

2-Hydroxytetrahydrothienopyridine derivatives resist hydrolysis to achieve faster onset of action and reduced bleeding risks.

Complexing polynucleotides with 3E10 antibodies protects genetic cargo from nuclease degradation and reduces immunogenicity during in vivo delivery.

Conjugating 2H-pyrazolo[4,3-d]pyrimidine compounds to antibodies directs immune stimulation precisely to target cells.

Replacing folic acid with 5-methyl-(6S)-tetrahydrofolate in oral contraceptives prevents neural tube defects without masking vitamin B12 deficiency symptoms.

Combining GalNAc-conjugated oligonucleotides with oral TLR7 agonists suppresses HBV replication while activating innate immunity.

Targeting serum hyaluronan with specific inhibitors prevents inflammation and severe clinical outcomes in dengue fever.

Teclistamab-cqyv engages CD3 T cells to destroy BCMA-positive cancer cells in relapsed multiple myeloma patients.

Segmented Eudragit layers resolve pH variability contradictions to deliver stable drug release for inflammatory bowel disease treatment.

Hydroxypropyl-alpha-cyclodextrin clathrates modulate the phosphoinositide cycle to improve autophagy and reduce lysosomal stress without ototoxicity.

Monomeric modules penetrate cell membranes and undergo click chemistry to form high-affinity oligomers that inhibit toxic RNA repeats.

Allosteric FSHR antagonists suppress disease progression while minimizing bone mass loss, extending treatment duration beyond six months.

Thiazole-substituted aminopyrimidines inhibit spleen tyrosine kinase activity through localized molecular design.

Dendrimer formulations complexed with N-acetyl cysteine shift macrophages from M1 to M2 phenotypes, resolving inflammation without systemic side effects.

RIPK1 inhibitor compounds modulate inflammatory responses and cell death pathways to treat diseases associated with excessive inflammation.

Nanoparticle-assembled coacervates resolve diffusion instability by restricting macromolecular exchange to maintain spatiotemporal heterogeneity.

A transdermal cream combines cannabidiol and gamma amino butyric acid to deliver analgesic relief through the skin.

Pyrazolo[1,5-a]pyrazin-4-yl derivatives selectively inhibit TYK2 without interfering with JAK2-dependent signaling pathways.

Stable crystalline forms of a Bruton's Tyrosine Kinase inhibitor enable direct precipitation from reaction mixtures.

Viral delivery of p53 up-regulators reduces hepatic steatosis by resolving unclear links between p53 and lipid metabolism.

Aldose reductase inhibitors diminish acute respiratory distress syndrome severity by suppressing inflammatory responses and limiting viral replication.

FL118 formulation inhibits survivin and Mcl-1 to overcome treatment resistance in metastatic cancers.

A tricyclic sulfone compound modulates RORγt activity through a specific V-1 linker structure.

Nanoparticle compositions bind antibodies to carrier proteins via hydrophobic interactions to maintain therapeutic activity during lyophilization.

Natural extracts replace recombinant cytokines to mobilize stem cells without severe side effects.

Specific plasticizers reduce particle friction to maintain candesartan cilexetil polymorphic form I, preventing decomposition during formulation.

Mutated HIV-1 gp120 polypeptides induce Env trimers into specific conformations to overcome latent viral reservoirs.

Measuring VEGF-D and PlGF expression levels predicts patient responsiveness to targeted cancer therapies.

A tablet formulation of sporoderm-disrupted Ganoderma lucidum spores uses enzymatic extraction to enhance bioavailability.

Orally disintegrating nefopam tablet formulation using taste-masked pellets and specific excipients for rapid oral dissolution.

Segmented capsules deliver vitamins to the large intestine, increasing Coprococcus spp. populations that conventional oral methods fail to nourish.

Novel branched 3-phenylpropionic acid derivatives directly activate soluble guanylate cyclase to induce vasorelaxation.

TBK1 kinase inhibitor compounds use selective binding to reduce off-target toxicity while maintaining therapeutic efficacy.

Buffered oral hyaluronic acid formulation maintains pH above 7.0 to prevent tooth enamel degradation while supporting joint lubrication.

Administers DHEA and acolbifene to increase testosterone levels while avoiding prostate volume expansion and cardiovascular risks.

Specific hydroxyl configurations convert DHA into pro-resolving compounds that enhance inflammation resolution.

Composite dextran hydrogels deliver synergistic growth factors to overcome limited vascular ingrowth in scaffolds.

Heteroaromatic compounds modulate dopamine D1 receptor activity to treat associated disorders.

A substituted steroidal derivative acts as a selective glucocorticoid receptor antagonist.

A humanized mouse model with a dystrophin exon 44 deletion enables precise therapeutic testing.

Substituted porphyrins rescue lung cells from sulfur mustard toxicity by reducing oxidative stress and mitochondrial dysfunction.

Combining S-equol with PD-1 inhibitors overcomes limited patient responsiveness in melanoma therapy.

Ultra-high binding affinity compensates for reduced CD22 expression on leukemia cells, preventing relapse and improving remission durability.

Chemical modifications resolve naked siRNA toxicity and poor neuronal delivery while maintaining robust C9orf72 gene silencing efficacy.

A plasticized matrix extrusion system deposits fibrous strands onto a moving stage to build three-dimensional structural frameworks.

Selective CB2 receptor modulators treat nociceptive and neuropathic pain without psychoactive side effects from CB1 activation.

Islatravir inhibits LINE1 reverse transcriptase activity, improving therapeutic efficacy while reducing adverse side effects.

Thienopyrimidine compounds inhibit Kv1.5 potassium channels, treating atrial fibrillation without affecting ventricular repolarization.

Local direct thrombin inhibition reduces mucosal damage and fecal bleeding scores by targeting pro-inflammatory thrombin activity in Crohn's disease.

Nano-liposome encapsulation of symmetrical curcumin analogs overcomes acquired chemo-resistance in Diffuse Large B-cell Lymphoma treatment.

A drug linker conjugate enables autocatalytic cleavage via cyclic imide formation to release the active moiety.

A wirelessly driven contact lens uses a transparent strain sensor to measure intraocular pressure changes in real time.

An acrylate-vinyl acetate copolymer with free hydroxyl groups stabilizes adhesion across temperature variations while maintaining painless removal.

Carbamate ester linkers transform short-acting halogenated carboxamides into stable prodrugs, resolving limited duration and solubility constraints.

Local quality modifications on the indolizine core reduce cross-reactivity with anti-target kinases like p38alpha while maintaining brain permeability.

Cooling agent agitation separates trichomes from cannabis plant material, reducing water consumption and solvent requirements.

Specific Cmax and AUC ranges guide dosing to resolve unclear PK-efficacy relationships in neurodegenerative disease treatment.

Enzymatic pretreatment modifies cellulose pulp structure before mechanical disintegration to yield nanofibrillar cellulose.

A T cell redirecting bispecific therapeutic uses a two-phase loading and maintenance dosage regimen to enhance clinical efficacy.

Acidic oral suspension with mesoporous silica prevents temozolomide recrystallization and degradation for precise pediatric dosing.

Selective Bdfl inhibitors exploit structural differences to treat drug-resistant fungal infections without human toxicity.

DNAzymes targeting GATA-3 reduce allergen responses and IL-5 levels in patients with high eosinophil counts.

Epoxide ring-opening stabilizes ascorbic acid derivatives, suppressing coloration and odor while maintaining whitening activity without complex synthesis.

Combining CRAF and ERK inhibitors overcomes resistance mechanisms in KRAS-mutant cancers, achieving durable tumor regression where single agents fail.

Dissolving tacrolimus in DMSO stabilizes the drug for aqueous delivery, enabling calcineurin inhibition that initiates fin regeneration.

Purified albumin paclitaxel nanoparticles encapsulate the drug via hydrophobic interactions to improve water solubility while removing toxic surfactants.

Cyclic deoxyribonucleotide prodrugs utilize CYP3A4 activation to resolve the contradiction between short biological half-life and systemic toxicity.

Conjugating doxorubicin with estradiol prevents nuclear accumulation, resolving systemic toxicity while maintaining anticancer efficacy.

Topical enavogliflozin eye drops replace invasive intravitreal injections, resolving compliance and side effect risks while maintaining therapeutic efficacy.

IGFBP7 inhibitors target pathological cardiac hypertrophy and fibrosis, improving diastolic function in heart failure with preserved ejection fraction.

Carrier-linked oligomer conjugates down-regulate HBx and HBsAg expression by overcoming cell membrane penetration barriers.

Segmented heteroaryl compounds use reactive warhead groups to covalently bind protein kinases, extending duration of action while maintaining selectivity.

A medicament containing a compound with melatonin receptor affinity targets neurodevelopmental pathways to treat autism spectrum disorder.

A catechin glycoside extract from Ulmus plants inhibits adipocyte differentiation while protecting muscle cells.

Tricyclic heterocyclic compounds resolve selectivity versus breadth trade-offs by targeting CSF-1R kinase activity to reduce metastasis.